A Phase 1 study of IMGN632, a CD123-targeted ADC for the treatment of hematological malignancies.
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs IMGN-632 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 16 Oct 2017 According to an ImmunoGen media release, the U.S. Food and Drug Administration (FDA) has completed the safety review of its investigational new drug (IND) application and company plans to open study to enrollment before the end of the year.
- 01 Sep 2017 New trial record
- 29 Aug 2017 According Jazz Pharmaceuticals plc media release, ImmunoGen expects to file an investigational new drug application (IND) for IMGN632 this quarter and planning to enroll first patient before the end of the 2017.